Root Financial Partners
DSGN icon

Root Financial Partners’s Design Therapeutics DSGN Stock Holding History

Root Financial Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$440 Buy
+35
New +$484 ﹤0.01% 3264
2026
Q2 		– Sell
-38
Closed -$404 – 1160
2026
Q1 		$404 Buy
+38
New +$384 ﹤0.01% 2940

Other funds holding DSGN

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Root Financial Partners's DSGN Position: Q3 2026 in Review

Root Financial Partners opened a new position in Design Therapeutics (DSGN) in Q3 2026: 35 shares worth $440. The stake represents ﹤0.01% of the portfolio and ranks #3264 among its holdings. This is a return to the name: Root Financial Partners previously reported a position in DSGN as recently as Q1 2026.

Root Financial Partners first reported a position in DSGN in Q1 2026 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • Root Financial Partners held 35 shares of Design Therapeutics worth $440 as of Q3 2026.
  • Design Therapeutics was a new Root Financial Partners position in Q3 2026.
  • Design Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3264 holding.
  • Root Financial Partners first reported a position in Design Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.